Molecular mechanisms of Polyphyllin I-induced apoptosis and reversal of the epithelial-mesenchymal transition in human osteosarcoma cells

Journal of Ethnopharmacology

Volumn 170, Issue , 2015, Pages 117-127

  Chang, Junli ^a,b   Wang, Hongshen ^a,b   Wang, Xianyang ^a,b   Zhao, Yongjian ^a,b   Zhao, Dongfeng ^a,b   Wang, Chenglong ^a,b   Li, Yimian ^a,b   Yang, Zhilie ^a,b   Lu, Sheng ^a,b   Zeng, Qinghua ^c,d   Zimmerman, Jacquelyn ^d   Shi, Qi ^a,b   Wang, Yongjun ^a,b   Yang, Yanping ^a,b  

^a LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c JILIN UNIVERSITY   (China)

^d Heerskink School of Medicine   (United States)

Author keywords

Apoptosis; Cell cycle; Epithelialmesenchymal transition; Osteosarcoma; Polyphyllin I; Proteasome activity

Indexed keywords

ANTINEOPLASTIC AGENT; CDK1 PROTEIN; CYCLIN B1; CYCLIN D1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; POLYPHYLLIN I; PROTEIN; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; APOPTOSIS REGULATORY PROTEIN; DIOSGENIN; PROTEASOME;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIVISION; CELL GROWTH; CELL INVASION; CELL LYSATE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHINESE MEDICINE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HERBAL MEDICINE; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SAOS 2 CELL LINE; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; CHEMISTRY; DRUG EFFECTS; ISOLATION AND PURIFICATION; LILIACEAE; METABOLISM; MOLECULARLY TARGETED THERAPY; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

GASTROPODA; PARIS POLYPHYLLA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE NEOPLASMS; CELL LINE, TUMOR; DIOSGENIN; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LILIACEAE; MOLECULAR TARGETED THERAPY; OSTEOSARCOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; UP-REGULATION;

EID: 84930656124     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2015.05.006     Document Type: Article

References (44)

1. J. Adams, V.J. Palombella, E.A. Sausville, J. Johnson, A. Destree, D.D. Lazarus, J. Maas, C.S. Pien, S. Prakash, and P.J. Elliott Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res. 59 1999 2615 2622
2. B. An, R.H. Goldfarb, R. Siman, and Q.P. Dou Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts Cell Death Differ. 5 1998 1062 1075
3. C.M. Annunziata, R.E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, G. Wright, W. Xiao, S. Dave, E.M. Hurt, B. Tan, H. Zhao, O. Stephens, M. Santra, D.R. Williams, L. Dang, B. Barlogie, J.D. Shaughnessy Jr., W.M. Kuehl, and L.M. Staudt Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma Cancer Cell 12 2007 115 130
4. R.R. Arvizo, S. Saha, E. Wang, J.D. Robertson, R. Bhattacharya, and P. Mukherjee Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle Proc. Natl. Acad. Sci. USA 110 2013 6700 6705
5. P.A. Baeuerle, and D. Baltimore I kappa B: a specific inhibitor of the NF-kappa B transcription factor Science 242 1988 540 546
6. A.S. Baldwin Regulation of cell death and autophagy by IKK and NF-kappaB: critical mechanisms in immune function and cancer Immunol. Rev. 246 2012 327 345
7. A. Barrallo-Gimeno, and M.A. Nieto The Snail genes as inducers of cell movement and survival: implications in development and cancer Development 132 2005 3151 3161
8. I.K. Bukholm, J.M. Nesland, and A.L. Borresen-Dale Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments] J. Pathol. 190 2000 15 19
9. A.J. Chou, and R. Gorlick Chemotherapy resistance in osteosarcoma: current challenges and future directions Expert Rev. Anticancer Ther. 6 2006 1075 1085
10. J.C. Clark, C.R. Dass, and P.F. Choong A review of clinical and molecular prognostic factors in osteosarcoma J. Cancer Res. Clin. Oncol. 134 2008 281 297
11. V.G. Cooke, V.S. LeBleu, D. Keskin, Z. Khan, J.T. O'Connell, Y. Teng, M.B. Duncan, L. Xie, G. Maeda, S. Vong, H. Sugimoto, R.M. Rocha, A. Damascena, R.R. Brentani, and R. Kalluri Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway Cancer Cell 21 2012 66 81
12. N. Erez, M. Truitt, P. Olson, S.T. Arron, and D. Hanahan Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner Cancer Cell 17 2010 135 147
13. C. Gallerne, A. Prola, and C. Lemaire Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2 Biochim. Biophys. Acta 1833 2013 1356 1366
14. J.R. Graff, J.G. Herman, R.G. Lapidus, H. Chopra, R. Xu, D.F. Jarrard, W.B. Isaacs, P.M. Pitha, N.E. Davidson, and S.B. Baylin E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas Cancer Res. 55 1995 5195 5199
15. C. Hetz, E. Chevet, and H.P. Harding Targeting the unfolded protein response in disease Nat. Rev. Drug Discov. 12 2013 703 719
16. T. Huang, Y. Zhu, X. Fang, Y. Chi, M. Kitamura, and J. Yao Gap junctions sensitize cancer cells to proteasome inhibitor MG132-induced apoptosis Cancer Sci. 101 2010 713 721
17. M. Jo, R.D. Lester, V. Montel, B. Eastman, S. Takimoto, and S.L. Gonias Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling J. Biol. Chem. 284 2009 22825 22833
18. D. Joyce, C. Albanese, J. Steer, M. Fu, B. Bouzahzah, and R.G. Pestell NF-kappaB and cell-cycle regulation: the cyclin connection Cytokine Growth Factor Rev. 12 2001 73 90
19. M. Jwa, and P. Chang PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1alpha-mediated unfolded protein response Nat. Cell Biol. 14 2012 1223 1230
20. M. Karin Nuclear factor-kappaB in cancer development and progression Nature 441 2006 431 436
21. M. Karin, and Y. Ben-Neriah Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity Annu. Rev. Immunol. 18 2000 621 663
22. U.G. Lopes p53-Dependent induction of apoptosis by proteasome inhibitors J. Biol. Chem. 272 1997 12893 12896
23. U.G. Lopes, P. Erhardt, R. Yao, and G.M. Cooper p53-Dependent induction of apoptosis by proteasome inhibitors J. Biol. Chem. 272 1997 12893 12896
24. A. Mani, and E.P. Gelmann The ubiquitin-proteasome pathway and its role in cancer J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 23 2005 4776 4789
25. N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and therapeutic advances for pediatric osteosarcoma Oncol. 9 2004 422 441
26. K.D. McCullough, J.L. Martindale, L.O. Klotz, T.Y. Aw, and N.J. Holbrook Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state Mol. Cell. Biol. 21 2001 1249 1259
27. L. Mirabello, R.J. Troisi, and S.A. Savage Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program Cancer 115 2009 1531 1543
28. D.P. Mishra, and N. Rastogi Therapeutic targeting of cancer cell cycle using proteasome inhibitors Cell Div, 2012, 7:26 2012
29. S. Nam, D.M. Smith, and Q.P. Dou Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo J. Biol. Chem. 276 2001 13322 13330
30. J.T. Nauseef, and M.D. Henry Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat. Rev. Urol. 8 2011 428 439
31. E.A. Obeng, L.M. Carlson, D.M. Gutman, W.J. Harrington Jr., K.P. Lee, and L.H. Boise Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood 107 2006 4907 4916
32. G. Ottaviani, and N. Jaffe The epidemiology of osteosarcoma Cancer Treat. Res. 152 2009 3 13
33. A.J. Pantuck, J. Liu, and H. Rettig, M.B. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas Cancer Res. 70 2010 752 761
34. N.D. Perkins The diverse and complex roles of NF-kappaB subunits in cancer Nat. Rev. Cancer 12 2012 121 132
35. A.K. Perl, P. Wilgenbus, U. Dahl, H. Semb, and G. Christofori A causal role for E-cadherin in the transition from adenoma to carcinoma Nature 392 1998 190 193
36. T.J. Sayers, and W.J. Murphy Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy Cancer Immunol. Immunother. 55 2006 76 84
37. J.M. Seeger, P. Schmidt, K. Brinkmann, A.A. Hombach, O. Coutelle, P. Zigrino, D. Wagner-Stippich, C. Mauch, H. Abken, M. Kronke, and H. Kashkar The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack Cancer Res. 70 2010 1825 1834
38. G. Shi, D. Chen, G. Zhai, M.S. Chen, Q.C. Cui, Q. Zhou, B. He, Q.P. Dou, and G. Jiang The proteasome is a molecular target of environmental toxic organotins Environ. Health Perspect. 117 2009 379 386
39. I. Tabas, and D. Ron Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress Nat. Cell Biol. 13 2011 184 190
40. I. Tagoug, L.P. Jordheim, S. Herveau, E.L. Matera, A.L. Huber, K. Chettab, S. Manie, and C. Dumontet Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 19 2013 3556 3566
41. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial-mesenchymal transitions in development and disease Cell 139 2009 871 890
42. W.K. Wu, C.H. Cho, C.W. Lee, K. Wu, D. Fan, J. Yu, and J.J. Sung Proteasome inhibition: a new therapeutic strategy to cancer treatment Cancer Lett. 293 2010 15 22
43. A.D. Yang, E.R. Camp, F. Fan, L. Shen, M.J. Gray, W. Liu, R. Somcio, T.W. Bauer, Y. Wu, D.J. Hicklin, and L.M. Ellis Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells Cancer Res. 66 2006 46 51
44. H. Yang, D. Chen, Q.C. Cui, X. Yuan, and Q.P. Dou Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice Cancer Res. 66 2006 4758 4765